HIK Hikma Pharmaceuticals PLC
Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, specialty, and branded pharmaceutical products. The company operates through three segments: Injectables, Hikma Rx, and Branded. The Injectables segment provides generic and specialty injectable products primarily for use in hospitals. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The Hikma Rx segment offers oral, respiratory, and other generic and specialty products for the retail market. It provides its products in various therapeutic areas, including respiratory, oncology, and pain management. The company also offers its products in solid, semi-solid, liquid, and injectable dosage forms. It operates in the United Kingdom, Europe, North America, the Middle East, North Africa, and internationally. Hikma Pharmaceuticals PLC was founded in 1978 and is headquartered in London, United Kingdom.…
Industry Peers
Drug Manufacturers - Specialty & GenericKey Statistics
About Hikma Pharmaceuticals (LON: HIK)
›
Hikma Pharmaceuticals (LON: HIK) is listed on the London Stock Exchange, where its shares trade in pence sterling (GBp). It belongs to the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector, and reports about 9,500 employees.
The shares were at 1687.00 GBp on 19 November 2026, up 7.0% over 52 weeks. Its 52-week range is 1187.00 GBp to 1762.00 GBp: the price is 4.3% below the high and 42.1% above the low.
At a market capitalisation of 3.49B GBP, it trades at 12.9 times trailing earnings and 9.2 times forward earnings. The median trailing P/E of its 17 largest Drug Manufacturers - Specialty & Generic peers is 24.7, a discount of 48% for HIK. It pays a dividend yielding 3.82% (it pays out 47% of its earnings), against a median of 1.90% among the dividend payers in that peer group.
Hikma Pharmaceuticals reports return on equity of 15.5%, an operating margin of 19.9% and revenue up 4.2% year over year.
Its debt exceeds its cash by 1.67B USD, a debt-to-equity ratio of 0.62. Its Piotroski F-score is 6 out of 9, an average reading of its financial health. 12 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 2030.01 GBp is 20.3% above the current price. The next earnings report is expected on 25 February 2027.